Close
Menu
In 2024, the US Supreme Court decision in United States Food and Drug Administration (FDA) v Alliance for Hippocratic Medicine (AHM) held that AHM, the plaintiffs, did not have standing, sending the case back to the lower court. While AHM has since voluntarily dismissed their case, a group of states hostile to abortion are continuing the litigation.
Advocacy
The Society has advocated for medication abortion practices and policies grounded in science by connecting legal partners and the courts to the evidence base demonstrating the safety and efficacy of mifepristone.
- Statement on the US Supreme Court’s decision in United States Food and Drug Administration (FDA) v Alliance for Hippocratic Medicine
- Joint statement urging the US Supreme Court to protect access to mifepristone ahead of oral arguments for AHM v FDA
- Amicus brief for the US Supreme Court in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, calling on the Court to stay the US District Court for the Northern District of Texas’s order blocking the FDA’s approval of mifepristone
- Amicus brief for the US Supreme Court supporting a stay on Judge Kacsmaryk’s decision in Alliance for Hippocratic Medicine v FDA
- Amicus brief for the Fifth Circuit supporting a stay on Judge Kacsmaryk’s decision in Alliance for Hippocratic Medicine v FDA
- Statement on Alliance for Hippocratic Medicine et al v US Food and Drug Administration ruling
Research
In pursuit of our vision of just and equitable abortion informed by science, the Society supports and uplifts research regarding the safety and efficacy of medication abortion.
- Increasing access to medication abortion
- Innovations in medication abortion service delivery
- Capturing tradeoffs in abortion care
- Science Says: Telehealth medication abortion is safe and effective
- #WeCount quarterly reports on the changes in abortion volumes following the Dobbs ruling
Clinical guidance
To support clinicians who administer medication abortion, the Society provides evidence-informed and person-centered guidance.
- SFP clinical recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation
- SFP interim clinical recommendation: Self-managed abortion
- Medication abortion up to 70 days of gestation
- Medication abortion with misoprostol-only: A sample protocol
Learning
The Society supports ongoing learning about medication abortion for clinicians, scholars, and advocates.